Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 31 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Arvinas Inc | ARVN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 34.00 | 08:44:58 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 34.00 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 3 | 31 | - | 13.57 - 53.08 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:38:24 | 1 | $ 34.84 | USD |
Arvinas Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.31B | 68.08M | - | 78.5M | -367.3M | -5.39 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Arvinas News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARVN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 33.73 | 35.865 | 32.6101 | 34.37 | 749,068 | 0.27 | 0.80% |
| 1 Month | 41.50 | 41.98 | 32.6101 | 36.55 | 600,998 | -7.50 | -18.07% |
| 3 Months | 39.49 | 53.08 | 32.6101 | 43.95 | 787,442 | -5.49 | -13.90% |
| 6 Months | 14.71 | 53.08 | 13.57 | 36.16 | 792,509 | 19.29 | 131.14% |
| 1 Year | 28.54 | 53.08 | 13.57 | 31.98 | 601,823 | 5.46 | 19.13% |
| 3 Years | 64.54 | 108.465 | 13.57 | 47.68 | 500,897 | -30.54 | -47.32% |
| 5 Years | 22.73 | 108.465 | 13.57 | 46.99 | 488,189 | 11.27 | 49.58% |
Arvinas Description
| Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
